Navigation Links
Stem Cell Therapy Disappoints Against Rare Kidney Ailment
Date:9/12/2007

Transplanted cells don't boost AL amyloidosis outcomes, study finds

WEDNESDAY, Sept. 12 (HealthDay News) -- In a disheartening result that confounds existing research, a team in France says a new stem cell therapy for a rare kidney disease is no better than the usual chemotherapy-only approach.

The study "has major limitations and must be interpreted with caution," said Dr. S. Vincent Rajkumar, a professor of medicine at the Mayo Clinic. Still, he said, it conflicts with "a widely held belief" that the stem-cell approach -- combined with aggressive chemotherapy -- is better for some patients.

But there's also some good news. The study doesn't reject the possibility that stem-cell transplants may be a better bet in facilities that specialize in the procedure, Rajkumar added.

The findings are published in the Sept. 13 issue of the New England Journal of Medicine.

AL amyloidosis disease is one of several caused by abnormal proteins that deposit themselves in various organs of the bodies and cause major damage, Rajkumar explained.

An estimated 1,200-3,200 people will develop the condition in the United States each year. The disease is similar to a more common condition called multiple myeloma.

Survival with AL amyloidosis is typically measured in months. The average survival time is a year without an effective treatment, said study lead author Dr. Arnaud Jaccard of the Centre Hospitalier Universitaire in Limoges, France.

But, according to Jaccard, there's plenty of controversy about which treatment is best.

In the new study, researchers followed two groups of 50 patients each. One group received treatment with high-dose chemotherapy (a drug called melphalan) followed by stem cell transplants; the other received standard-dose melphalan-plus-dexamethasone chemotherapy.

The researchers followed the patients for an average of three years to see what happened to them.

The team found no major difference in survival between the two groups.

There are some caveats, however, Rajkumar said. For one, few patients took part in the study, lowering its statistical power. For another, many of the patients who received stem-cell transplants got them at facilities that didn't have much experience in the procedure, which is very complicated, he said.

Considering that, it's possible that treatment with stem-cell treatments may be a better option in some cases, Rajkumar said.

More information

For more on AL amyloidosis, visit the Amyloidosis Support Network.



SOURCES: S. Vincent Rajkumar, M.D., professor, medicine, Mayo Clinic, Rochester, Minn.; Arnaud Jaccard, M.D., researcher, Centre Hospitalier Universitaire, Limoges, France; Sept. 13, 2007, New England Journal of Medicine


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Consensus on "Combination Therapy" for Breast Cancer
3. Acupuncture May Help Chemotherapy Side Effects
4. Antioxidants protect health tissue in people undergoing radiation therapy.
5. Distraction therapy found very effective in postoperative patients
6. Gene Therapy shows promise in treating Hemophilia
7. "Make AIDS Therapy affordable" - Physicians demand
8. Acupuncture superseeds massage therapy for short term relief of pain
9. Hormone replacement Therapy a headache
10. Simple Therapy
11. Ovarian cancer in relationship with Hormone therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017 ... has recognized the company with their  2017 New Product Innovation ... is based on extensive primary and secondary medical device market ... AVACEN Medical, through its first-to-market OTC, drug-free pain relief product, ... a unique approach to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
Breaking Medicine Technology: